Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors (Q44578123)

4 December 2017

Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors (English)

1 reference

4 December 2017

Yuka Sasakawa

1

1 reference

4 December 2017

Yoshinori Naoe

2

1 reference

4 December 2017

Takahisa Noto

3

1 reference

4 December 2017

Takeshi Inoue

4

1 reference

4 December 2017

Tatsuya Sasakawa

5

1 reference

4 December 2017

Masahiko Matsuo

6

1 reference

4 December 2017

Toshitaka Manda

7

1 reference

4 December 2017

Seitaro Mutoh

8

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

4 December 2017

Biochemical Pharmacology

1 reference

4 December 2017

66

1 reference

4 December 2017

6

1 reference

4 December 2017

897-906

1 reference

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

inferred from DOI database lookup

7 January 2021

based on heuristic

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Angiogenesis in cancer, vascular, rheumatoid and other disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Mechanisms of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

What Is the Evidence That Tumors Are Angiogenesis Dependent?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Differential regulation of the fibroblast growth factor (FGF) family by alpha(2)-macroglobulin: evidence for selective modulation of FGF-2-induced angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Characterization of a human RPD3 ortholog, HDAC3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

A positive role for histone acetylation in transcription factor access to nucleosomal DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

The transcriptional coactivators p300 and CBP are histone acetyltransferases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

The CBP co-activator is a histone acetyltransferase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Histone acetylation in chromatin structure and transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

Patterns of histone acetylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

The language of covalent histone modifications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900411-8

10.1016/S0006-2952(03)00411-8

7 January 2021

Identifiers

DOI

1 reference

4 December 2017

1 reference